This information is for educational purposes only and does not constitute medical advice.
CJC-1295
Also known as: CJC-1295 DAC, Modified GRF 1-29
A synthetic analogue of growth hormone-releasing hormone (GHRH) studied for sustained growth hormone elevation.
Quick Facts
- Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
- Molecular Weight
- 3367.97 Da
Overview
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids. It exists in two forms: with and without Drug Affinity Complex (DAC). The DAC version binds to albumin, extending its half-life significantly. The non-DAC version (also called Modified GRF 1-29) has a shorter duration of action.
Research has investigated its ability to increase sustained GH and IGF-1 levels.
Mechanism of Action
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone synthesis and release. The DAC modification allows albumin binding, extending plasma half-life from minutes to days. This results in sustained elevation of GH and IGF-1 levels rather than the pulsatile pattern of natural GH release.
Biological Pathways
Research Findings
Phase II clinical trials showed sustained increases in GH and IGF-1 levels. Studies demonstrated increased lean body mass and lipid metabolism changes. However, development for clinical use has stalled. Research continues in combination with GH secretagogues. Concerns remain about non-physiological GH patterns.
Risks & Safety Concerns
Potential risks include water retention, joint pain, carpal tunnel symptoms, disruption of normal GH pulsatility, potential effects on glucose metabolism, and theoretical cancer risk from chronic IGF-1 elevation. One serious adverse event (death) was reported during clinical trials, though causality was not established.
Regulatory & Legal Status
Not approved for human use by any major regulatory agency. Available as a research peptide. Listed on WADA prohibited list. Subject to increasing regulatory scrutiny.
Have questions about CJC-1295?
Ask our AI research assistant for educational information about this peptide.
Ask AI AssistantDisclaimer
This platform is for educational and research purposes only. The information provided does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health-related decisions.
The authors and contributors of this platform are not medical professionals, licensed physicians, or pharmacists. The content presented herein has been compiled from publicly available research and peer-reviewed literature for informational purposes only. No information on this platform should be interpreted as a recommendation to buy, sell, or use any substance. Any decision to use peptides or related compounds should be made solely under the guidance of a qualified healthcare provider. We assume no liability for actions taken based on information provided on this platform.